Regeneron Pharmaceuticals - Largest Companies by Marketcap, Revenue, Net Income and Employees
Top Corporates Hub
Regeneron Pharmaceuticals
REGN
|
NASDAQ
|
United States
235
-107
Rank
$115.11B
Market Cap
$14.20B
+$ 1.09B
+8.31%
Revenue
$4.77B
+$ 0.12B
+2.58%
Earnings
15.2K
+1.7K
+12.7%
Employees
About
Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
- Sector: Health Technology
- Industry: Pharmaceuticals: Major
- Headquarters:
Latest News
-
REGN or ILMN: Which Is the Better Value Stock Right Now?
09.04.2026 -
Bernstein Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $921
08.04.2026 -
Regeneron Pharma Now Expects Q1 GAAP And Non-GAAP Results To Include Acquired IPR&D Charge Of ~$102M On Pre-Tax Basis
08.04.2026 -
Regeneron Eyes Longer EYLEA HD Dosing As Valuation Gap Persists
04.04.2026 -
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
03.04.2026